Carregant...
Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway
AIM: Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer. However, only part of patients benefit from regorafenib, and the mechanisms of regorafenib’s anti-tumor effect need furthe...
Guardat en:
| Publicat a: | PLoS One |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5425213/ https://ncbi.nlm.nih.gov/pubmed/28489887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0177335 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|